Last reviewed · How we verify
GnRHa with Tamoxifen
GnRHa suppresses estrogen production while tamoxifen blocks estrogen receptor signaling, providing dual hormonal inhibition for hormone-sensitive breast cancer.
GnRHa suppresses estrogen production while tamoxifen blocks estrogen receptor signaling, providing dual hormonal inhibition for hormone-sensitive breast cancer. Used for Hormone receptor-positive breast cancer in premenopausal women.
At a glance
| Generic name | GnRHa with Tamoxifen |
|---|---|
| Also known as | Endocrine Therapy |
| Sponsor | Asan Medical Center |
| Drug class | GnRH agonist + selective estrogen receptor modulator (SERM) combination |
| Target | GnRH receptor (GnRHR) and estrogen receptor (ER) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gonadotropin-releasing hormone agonists (GnRHa) downregulate the hypothalamic-pituitary-gonadal axis, reducing ovarian estrogen synthesis in premenopausal women. Tamoxifen acts as a selective estrogen receptor modulator (SERM), competitively blocking estrogen binding to its receptor on breast cancer cells. The combination provides complementary hormonal suppression and receptor antagonism.
Approved indications
- Hormone receptor-positive breast cancer in premenopausal women
Common side effects
- Hot flashes
- Vaginal bleeding/spotting
- Nausea
- Arthralgia
- Endometrial thickening
Key clinical trials
- Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer (PHASE3)
- Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GnRHa with Tamoxifen CI brief — competitive landscape report
- GnRHa with Tamoxifen updates RSS · CI watch RSS
- Asan Medical Center portfolio CI